Browsing by Subject "Patient monitoring"
Now showing items 1-8 of 8
-
Article
Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients
(1996)A total of 209 postsurgical breast cancer patients were prospectively monitored with simultaneous serum level estimations of CA 15-3, mucin-like carcinoma-associated antigen (MCA), tumor polypeptide antigen (TPA), and ...
-
Article
G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting
(2001)BACKGROUND. Cancer antigen 15-3 (CA 15-3), a circulating marker that determines secreted products of the polymorphic MUC1 gene, has been established as a convenient tool for monitoring breast carcinoma patients. METHODS. ...
-
Conference Object
Intensive care window: A multi-modal monitoring tool for intensive care research and practice
(2007)Intensive Care Units are widely considered as the most technologically advanced environments within a hospital. In such environments, physicians are confronted with multiple medical devices that monitor the inpatients. The ...
-
Article
Is the mortality rate for septic shock really decreasing?
(2008)Survival rates for patients in septic shock have gradually improved in critical care units worldwide over the last 25 years. Further improvement will be predicated on the discovery of new therapies to disrupt the underlying ...
-
Article
Metastatic breast cancer with liver metastases: A registry analysis of clinicopathologic, management and outcome characteristics of 500 women
(2006)Introduction. Breast cancer patients developing liver metastases have traditionally been considered to make up a poor prognosis group with median survival rates of less than 6 months. We retrospectively analysed clinicopathologic ...
-
Article
Personalized medicine in sepsis: The coming of age
(2013)"a there is both the need to discover specific and clinically useful biomarkers in order to diagnose sepsis, define the hosta s immune status, monitor treatment and define prognosis and to develop medications that would ...
-
Article
A retrospective analysis of serum CA 15-3 concentrations in patients with localised or metastatic renal cancer and its impact on prognosis and follow-up. A single-centre experience
(2002)Background. Monitoring patients with renal cancer for recurrence or progression is ineffective, inconvenient and costly. We conducted a retrospective analysis of serum CA 15-3 concentrations in a single-centre patient ...
-
Article
Weekly paclitaxel combined with pegylated liposomal doxorubicin (Caelyx ™) given every 4 weeks: Dose-finding and pharmacokinetic study in patients with advanced solid tumors
(2004)Background: We aimed to define the maximum tolerated dose (MTD) and characterize the toxicity of the combination of pegylated liposomal doxorubicin (PLD; Caelyx™) and weekly paclitaxel (wPTX), and to investigate pharmacokinetics ...